# Fasting and Nutrition as Promising Treatment Strategies for Women with Rheumatoid Arthritis in Transitional Hormonal Stages

**Authors:** Bérénice Hansen, Evdokia Alvanou, Maria Angeliki S. Pavlou, Paul Wilmes, Jochen G. Schneider

PMC · DOI: 10.3390/nu18040580 · Nutrients · 2026-02-10

## TL;DR

This paper reviews how fasting and nutrition can help manage rheumatoid arthritis in women during hormonal transitions like menopause.

## Contribution

It highlights fasting and plant-based diets as promising complementary strategies for RA management during hormonal changes.

## Key findings

- Fasting may reduce inflammation and modulate immune activity in RA patients.
- Plant-based diets could improve gut health and reduce oxidative stress linked to RA.
- Nutritional interventions may support better disease outcomes during hormonal transitions.

## Abstract

Rheumatoid arthritis (RA) is a systemic and chronic autoimmune disease affecting about 1% of the global population, with a higher prevalence in women. Its treatment has been improved greatly over the past 30 years but there is no definitive cure available, and another unmet need exists for transitional hormonal stages such as pregnancy or menopause, which spurs the need to research new therapy options. In recent years, dietary interventions, particularly fasting and plant-based nutrition, have gained attention for their potential to alleviate RA symptoms. Fasting has been shown to reduce systemic inflammation, promote autophagy, and modulate immune cell activity, possibly leading to decreased joint pain and swelling. Nutritional strategies, such as anti-inflammatory and plant-based diets, have been shown to impact the gut microbiome and potentially support weight management, improve metabolic health, and reduce oxidative stress, all of which might contribute to better RA disease outcomes. Although the precise mechanisms remain under investigation, these approaches offer promising complementary strategies for enhancing RA management and improving patients’ quality of life. This review explores the preventive and therapeutic potential of fasting and nutrition in RA, and their possible application in the context of hormonal fluctuations and transitional stages during a women’s life.

## Linked entities

- **Diseases:** rheumatoid arthritis (MONDO:0008383)

## Full-text entities

- **Genes:** PRKAB1 (protein kinase AMP-activated non-catalytic subunit beta 1) [NCBI Gene 5564] {aka AMPK, HAMPKb}, HP (haptoglobin) [NCBI Gene 3240] {aka HP2ALPHA2, HPA1S}, AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}, ESR2 (estrogen receptor 2) [NCBI Gene 2100] {aka ER-BETA, ESR-BETA, ESRB, ESTRB, Erb, NR3A2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** PBD (MESH:D010939), systemic (MESH:D015619), overweight (MESH:D050177), NCDs (MESH:D000073296), mood disruption (MESH:D019964), AIDs (MESH:D001327), vasomotor (MESH:D012223), arteriovenous ductus (MESH:D001165), obese (MESH:D009765), cognitive dysfunction (MESH:D003072), lupus (MESH:D008180), cartilage degradation (MESH:D002357), PMS (MESH:D011293), genitourinary symptoms (MESH:D000091642), Turner syndrome (MESH:D014424), multiple sclerosis (MESH:D009103), intestinal (MESH:D007410), pain (MESH:D010146), stiffness (MESH:C566112), PCOS (MESH:D011085), MD (MESH:D007161), nutrient deficiencies (MESH:D007153), malnourishment (MESH:D044342), monoarticular disease (MESH:D004194), injury to (MESH:D014947), articular inflammation (MESH:D007249), headaches (MESH:D006261), RA (MESH:D001172), erosions (MESH:D014077), bone loss (MESH:D001847), joint pain (MESH:D018771), Klinefelter (XXY) and Triple X (XXX) syndromes (MESH:C535318), weight (MESH:D015431), joints (MESH:D007592), swelling (MESH:D004487), irritability (MESH:D001523), AD (MESH:D000544), fibromyalgia (MESH:D005356), cardiovascular disease (MESH:D002318), oral infections (MESH:D007239), synovitis (MESH:D013585), Dysbiosis (MESH:D064806), gastrointestinal complications (MESH:D005767), bad breath (MESH:D012120)
- **Chemicals:** MTX (MESH:D008727), steroid (MESH:D013256), blood glucose (MESH:D001786), 1,25-dihydroxyvitamin D (MESH:C097949), sugar (MESH:D000073893), fat (MESH:D005223), PF (-), GMB (MESH:C032138), bile acid (MESH:D001647), oestriol (MESH:D004964), lithocholic acid (MESH:D008095), leflunomide (MESH:D000077339), malondialdehyde (MESH:D008315), carbohydrate (MESH:D002241)
- **Species:** Bacillota (clostridial firmicutes, phylum) [taxon 1239], gut metagenome (species) [taxon 749906], Porphyromonas gingivalis (species) [taxon 837], Aggregatibacter actinomycetemcomitans (species) [taxon 714], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12942644/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12942644/full.md

## References

71 references — full list in the complete paper: https://tomesphere.com/paper/PMC12942644/full.md

---
Source: https://tomesphere.com/paper/PMC12942644